Drugs / BGC515
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06452160 | Jun 2024 → Jun 2027 expected | epithelioid hemangioendothelioma, mesothelioma | BridGene Biosciences Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-07 | BridGene Biosciences Inc. | Regulatory BridGene Biosciences Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor BGC515 bridgenebio.com ↗
BridGene Biosciences, Inc., a pioneer in the development of covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the clinical study of its TEAD inhibitor BGC515 for the treatment of cancers harboring genetic mutations in the hippo signaling pathway. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-27 | BridGene Biosciences Inc. | BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors bridgenebio.com ↗ |
| 2024-03-07 | BridGene Biosciences Inc. | BridGene Biosciences Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor BGC515 bridgenebio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGC515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06452160 ↗ |
| Route | Oral | “BGC515 Capsules will be administered orally” NCT06452160 ↗ |